Iovance Biotherapeutics, Inc. $IOVA Position Cut by American Century Companies Inc.

American Century Companies Inc. decreased its holdings in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 80.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,974 shares of the biotechnology company's stock after selling 101,680 shares during the quarter. American Century Companies Inc.'s holdings in Iovance Biotherapeutics were worth $83,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Baird Financial Group Inc. boosted its position in shares of Iovance Biotherapeutics by 1.0% during the 4th quarter. Baird Financial Group Inc. now owns 195,845 shares of the biotechnology company's stock valued at $1,449,000 after acquiring an additional 2,000 shares during the last quarter. Algert Global LLC raised its holdings in Iovance Biotherapeutics by 4.3% in the fourth quarter. Algert Global LLC now owns 56,400 shares of the biotechnology company's stock valued at $417,000 after acquiring an additional 2,330 shares in the last quarter. Avantax Advisory Services Inc. raised its holdings in Iovance Biotherapeutics by 39.0% in the first quarter. Avantax Advisory Services Inc. now owns 18,560 shares of the biotechnology company's stock valued at $62,000 after acquiring an additional 5,205 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in Iovance Biotherapeutics by 12.9% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 45,877 shares of the biotechnology company's stock valued at $153,000 after acquiring an additional 5,237 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. increased its stake in Iovance Biotherapeutics by 39.4% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 19,442 shares of the biotechnology company's stock valued at $144,000 after purchasing an additional 5,500 shares during the last quarter. Institutional investors and hedge funds own 77.03% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on IOVA. UBS Group lowered shares of Iovance Biotherapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $17.00 to $2.00 in a research report on Friday, May 16th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Iovance Biotherapeutics in a research report on Tuesday, August 19th. Zacks Research upgraded shares of Iovance Biotherapeutics to a "hold" rating in a research report on Tuesday, August 12th. Chardan Capital decreased their target price on shares of Iovance Biotherapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Finally, The Goldman Sachs Group lowered shares of Iovance Biotherapeutics from a "neutral" rating to a "sell" rating in a research report on Tuesday, July 15th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $11.90.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA traded down $0.15 on Friday, reaching $2.27. The stock had a trading volume of 8,510,418 shares, compared to its average volume of 10,704,390. The company has a market cap of $821.40 million, a price-to-earnings ratio of -1.85 and a beta of 0.82. The firm's fifty day moving average is $2.44 and its two-hundred day moving average is $2.68. Iovance Biotherapeutics, Inc. has a 12-month low of $1.64 and a 12-month high of $12.51.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.04). The company had revenue of $59.95 million for the quarter, compared to analyst estimates of $67.14 million. Iovance Biotherapeutics had a negative net margin of 161.44% and a negative return on equity of 52.87%. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current fiscal year.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.